NCT05838209 is a NA clinical trial of test in Periodontal Diseases, sponsored by Universidade Federal Fluminense.

Who is sponsoring NCT05838209?

NCT05838209 is sponsored by Universidade Federal Fluminense.

What drugs are being tested in NCT05838209?

Interventions in NCT05838209: test, Control.

What condition does NCT05838209 study?

NCT05838209 studies Periodontal Diseases.

Is NCT05838209 still recruiting?

NCT05838209 is currently status unknown. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT05838209

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Ozone Oil After Non-surgical Periodontal Treatment

Status unknown NA Last updated 7 June 2023

What this trial tests

NA trial testing test in Periodontal Diseases in 16 participants. Status unknown.

Timeline

5 April 2023

Primary endpoint
1 June 2023

1 July 2023

Quick facts

Lead sponsor	Universidade Federal Fluminense
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	5 April 2023
Primary completion	1 June 2023
Estimated completion	1 July 2023
Sites	1 location across Brazil

Drugs / interventions tested

test — full drug profile →
Control

Conditions studied

Periodontal Diseases — all drugs for Periodontal Diseases →

Sponsor

Universidade Federal Fluminense — full company profile →

Who can join

Adults 18 to 70, any sex, with Periodontal Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the use of ozone oil as an adjunctive of non-surgical periodontal treatment (NSPT) on diabetics type 2 patients (DM2) compared to control group with chronic periodontal disease. The principal question is to evaluate if the ozone oil could improve periodontal clinical parameters. Thirty-two sites of 16 diabetics type 2 patients (DM2) with moderate to advanced periodontal disease containing two sites with periodontal pocket depth (PPD) of \> 5 mm were selected. The treatment was distributed in 2 groups in the split mouth design: Control- scaling and root planing + saline solution (control) and Test - scaling and root planning + ozone oil

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of ozone oil and non-surgical periodontal treatment in patients with type 2 diabetes. In-vivo and in-vitro studies with fibroblasts and Candida albicans.
Carmo RAD, Cörner ACO, Martins EF, Ouverney G, et al · · 2025 · cited 2× · PMID 39841769 · DOI 10.1590/1678-7757-2024-0080

Verify or expand the search:

Other trials of test

Trials testing the same drug.

NCT07150078 — Dual Task and Attention Deficit and Hyperactivity Disorder · completed
NCT04631497 — Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19 · completed

Other recruiting trials for Periodontal Diseases

Currently open trials in the same condition.

NCT07358104 — Efficacy of Camel Whey Protein and Camel Whey Protein Nanoparticles for Treating Intra-bony Periodontal Defects · NA · active not recruiting
NCT07312045 — HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical T · recruiting
NCT07384221 — Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients · recruiting
NCT07530978 — ORAL HYGIENE, PERIODONTAL STATUS AND QUALITY OF LIFE · recruiting
NCT06848790 — Interdental Hygiene Methods in Young Adults · NA · recruiting

Other Universidade Federal Fluminense trials

Trials by the same sponsor.

NCT06394531 — Effects of Jaboticaba (Plinia Cauliflora) Supplementation in Chronic Kidney Disease Patients · NA · not yet recruiting
NCT06394544 — Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment · NA · not yet recruiting
NCT06286735 — Effects of Cinnamomum Supplementation in Chronic Kidney Disease Patients · NA · not yet recruiting
NCT06288204 — Green Propolis Extract and Royal Jelly in Hypertensive Patients and/or With Chronic Kidney Disease · NA · recruiting
NCT06917131 — Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05838209 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidade Federal Fluminense
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05838209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing